Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,418,966
  • Shares Outstanding, K 43,210
  • Annual Sales, $ 1,599 M
  • Annual Income, $ 713,700 K
  • 36-Month Beta 1.38
  • Price/Sales 3.39
  • Price/Cash Flow 7.14
  • Price/Book 2.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.79 +7.14%
on 10/27/17
130.69 -5.08%
on 10/25/17
+5.15 (+4.33%)
since 10/24/17
3-Month
114.54 +8.30%
on 09/22/17
136.17 -8.90%
on 09/06/17
-5.81 (-4.47%)
since 08/24/17
52-Week
112.01 +10.75%
on 04/26/17
169.89 -26.98%
on 02/21/17
-7.34 (-5.59%)
since 11/23/16

Most Recent Stories

More News
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

CELG : 104.95 (-0.20%)
CYTK : 7.60 (-4.76%)
RARE : 48.82 (-0.25%)
ACOR : 20.70 (+2.22%)
TSRO : 83.42 (-0.58%)
UTHR : 124.25 (-0.92%)
BIIB : 309.38 (-0.14%)
United Therapeutics PAH Drug's Exclusivity Period Extended

United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

JNJ : 137.77 (+0.35%)
LLY : 84.11 (+0.51%)
GILD : 72.60 (-0.30%)
UTHR : 124.25 (-0.92%)
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca®

United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Adcirca® (tadalafil) tablets through May 21, 2018,...

UTHR : 124.25 (-0.92%)
Pre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and Depomed

If you want a Stock Review on SGYP, NVO, UTHR, or DEPO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com redirects investors' attention...

NVO : 52.20 (+0.69%)
SGYP : 1.91 (+0.53%)
UTHR : 124.25 (-0.92%)
DEPO : 6.30 (-0.16%)
SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit

SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today...

STDY : 3.05 (-1.61%)
UTHR : 124.25 (-0.92%)
United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat

United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.

LGND : 134.03 (+0.73%)
NVO : 52.20 (+0.69%)
MDT : 83.22 (+1.07%)
UTHR : 124.25 (-0.92%)
Corporate News Blog - United Therapeutics Receives FDA Approval of Third Generation Nebulizer for Tyvaso Inhalation System

LONDON, UK / ACCESSWIRE / October 25, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for United Therapeutics Corp. (NASDAQ: UTHR), following which we...

UTHR : 124.25 (-0.92%)
United Therapeutics Corporation to Host Earnings Call

Work

UTHR : 124.25 (-0.92%)
United Therapeutics Corporation Reports Third Quarter 2017 Financial Results

United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2017.

UTHR : 124.25 (-0.92%)
United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation System

United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil)...

UTHR : 124.25 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.

See More

Key Turning Points

2nd Resistance Point 127.47
1st Resistance Point 126.44
Last Price 124.25
1st Support Level 124.58
2nd Support Level 123.75

See More

52-Week High 169.89
Fibonacci 61.8% 147.78
Fibonacci 50% 140.95
Fibonacci 38.2% 134.12
Last Price 124.25
52-Week Low 112.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart